[Identification of ion channel/transporter expression profiles in digestive cancer stem cells for novel targeting...

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Cancer stem cells (CSCs) are crucial for tumor growth and resistance.
• Targeting CSC-specific membrane transporters is a potential cancer therapy strategy.
• Ion channel expression in digestive CSCs remains largely unexplored.

Purpose of the Study:

• To investigate ion channel expression profiles in digestive CSCs.
• To evaluate the therapeutic potential of ion channel inhibitors against digestive CSCs.
• To identify novel therapeutic targets for digestive cancers.

Main Methods:

• Isolation of CSCs from esophageal, gastric, and pancreatic cancer cell lines using fluorescence-activated cell sorting (FACS) based on CSC markers (ALDH1A1, CD44).
• Identification of CSCs through tumorsphere formation assays.
• Microarray analysis to determine ion channel expression profiles (TRPV2, VGCCs, VGKCs).
• Assessment of cytotoxicity of ion channel inhibitors (tranilast, amlodipine, verapamil, 4-aminopyridine) in CSCs and non-CSCs.
• Validation of inhibitory effects in a xenograft mouse model.

Main Results:

• CSCs exhibited higher expression of CSC markers and resistance to anticancer agents compared to non-CSCs.
• TRPV2, VGCCs, and VGKCs were significantly upregulated in esophageal, gastric, and pancreatic CSCs, respectively.
• TRPV2, VGCCs, and VGKCs inhibitors demonstrated greater cytotoxicity against CSCs.
• Inhibitory effects were confirmed in vivo using a xenograft model.

Conclusions:

• Ion channels play a significant role in the persistence and drug resistance of CSCs.
• Targeting specific ion channels (TRPV2, VGCCs, VGKCs) with inhibitors represents a potential therapeutic strategy for digestive cancers.
• A Phase I/II clinical trial is underway to evaluate tranilast in advanced esophageal squamous cell carcinoma, supporting the clinical relevance of these findings.